SCHEMBL3210679

SCHEMBL3210679

COC(=O)c1cc(C)c(N)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CISD2 Q8N5K1 2/20 0.47
CSNK2A2 P19784 1/20 0.45
KDR P35968 1/20 0.45
CSNK2B P67870 1/20 0.45
CSNK2A1 P68400 1/20 0.45
ALDH1A1 P00352 5/20 0.42
HPGD P15428 5/20 0.42
KDM4E B2RXH2 4/20 0.42
MAPK1 P28482 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MEN1 O00255 3/20 0.42
MAPT P10636 3/20 0.42
KMT2A Q03164 3/20 0.42
DAO P14920 2/20 0.42
GAA P10253 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
LMNA P02545 1/20 0.41
PPARG P37231 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9806950 0.81 CISD2 (0.57) CISD2CSNK2A2KDRCSNK2BCSNK2A1
SCHEMBL9925990 0.80 KDM4E (0.67) CSNK2A2KDRCSNK2BCSNK2A1ALDH1A1
SCHEMBL24577254 0.78 HPGD (0.45) CISD2CSNK2A2KDRCSNK2BCSNK2A1
SCHEMBL3247261 0.78 KDR (0.43) CSNK2A2KDRCSNK2BCSNK2A1ALDH1A1
SCHEMBL24578032 0.78 MAPT (0.42) CISD2ALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL1417353 0.77 CSNK2A2 (0.45) CSNK2A2KDRCSNK2BCSNK2A1ALDH1A1
SCHEMBL18051446 0.77 CSNK2A2 (0.45) CSNK2A2KDRCSNK2BCSNK2A1ALDH1A1
SCHEMBL16302070 0.77 DAO (0.69) CSNK2A2KDRCSNK2BCSNK2A1ALDH1A1
SCHEMBL261464 0.77 CSNK2A2 (0.45) CSNK2A2KDRCSNK2BCSNK2A1ALDH1A1
SCHEMBL2304762 0.77 MCL1 (0.49) CSNK2A2KDRCSNK2BCSNK2A1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4267585-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS Actelion Pharmaceuticals Ltd (CH) 2023-11-01 EP disclosed
CN-112661754-B Polycyclic compound for inhibiting RNA helicase DHX33 成都开悦生命科技有限公司 2023-06-16 CN disclosed
WO-2022136509-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2022-06-30 WO disclosed
CN-112661754-A Polycyclic compound for inhibiting RNA helicase DHX33 成都开悦生命科技有限公司 2021-04-16 CN disclosed
EP-2991980-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2016-03-09 EP disclosed
WO-2014177982-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2014-11-06 WO disclosed
EP-2078002-B1 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS MERCK SHARP & DOHME (US) 2013-08-28 EP disclosed
US-8227605-B2 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors SCHERING CORPORATION (US) 2012-07-24 US disclosed
US-20100055090-A1 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS MERCK SHARP & DOHME LLC 2010-03-04 US disclosed
CN-101573345-A 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors SCHERING CORP (US) 2009-11-04 CN disclosed
EP-2078002-A1 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2009-07-15 EP disclosed
WO-2008054701-A1 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100055090-A1 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS MAPK15, CDK15, MAP3K15 CISD2 1112/4885CSNK2A2 118/4885KDR 821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.